Form 4: Revolution Medicines CFO Receives Equity Grant

Revolution Medicines' Chief Financial Officer, Jack Anders, was granted 20,200 shares of common stock and 45,400 stock options, effective March 1, 2026.

Summary

• Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (RVMD), acquired 20,200 shares of common stock.
• Anders also acquired 45,400 stock options with an exercise price of $102.02.
• These transactions occurred on March 1, 2026.
• The stock options will vest over four years, with 1/48th vesting monthly from March 1, 2026, contingent on Anders' continued service.
• Following these transactions, Anders beneficially owns 128,265 shares of common stock (including 62,538 restricted stock units) and 45,400 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive compensation practices that align management's interests with long-term shareholder value, without indicating any immediate operational changes or financial distress.

Positives

• The grant of common stock and stock options aligns the CFO's financial interests with long-term shareholder value.
• The four-year vesting schedule for the stock options encourages continued service and performance from a key executive.

Future Outlook

The vesting schedule for the stock options extends over four years from March 1, 2026, indicating a long-term incentive structure tied to the company's future performance and the CFO's continued service.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the CFO are standard practice in the biotechnology and pharmaceutical industries, aiming to retain talent and align executive incentives with long-term company growth and shareholder returns. This is particularly common in companies focused on drug development, where long-term commitment is crucial.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the biotech sector often include a mix of restricted stock units and stock options, similar to this grant.
• The four-year vesting schedule is a common industry standard for executive equity awards, comparable to practices at companies like Moderna or BioNTech for their senior leadership.
• The grant size relative to the executive's existing holdings and the company's market capitalization would typically be benchmarked against peer companies in similar stages of development or market cap.

Stakeholder Impact

• Shareholders: The equity grant aligns the CFO's financial interests with shareholder value creation over the long term.
• Employees: May signal stability in executive leadership and a commitment to long-term growth within the company.

Next Steps

• The stock options will vest monthly over the next four years, contingent on Jack Anders' continued service.

Key Dates

Recommendation

This Form 4 filing reports a standard equity compensation grant to a key executive, which is a routine event and does not provide new information that would warrant a change in investment thesis. It reinforces management's long-term alignment but doesn't signal a catalyst for immediate price movement.

Keywords

Revolution Medicines, RVMD, Jack Anders, CFO, Stock Grant, Stock Options, Equity Compensation, Insider Transaction, Form 4, Beneficial Ownership